Journal: Asian Pacific Journal of Cancer Prevention

Article Title: Comparative Study of ERK1/2, Bcl2, and Sorcin with Clinicopathological Characteristics of Gastric carcinoma: Tubular Adenocarcinoma Vs Signet Ring Cell Carcinoma

doi: 10.31557/apjcp.2025.26.5.1581

Figure Lengend Snippet: Figure 2. Haematoxylin and Eosin Staining of A. Tubular Adenocarcinoma (40X and 100X) B. Signet Ring Cell Carcinoma (40X and 100X). Immunostaining of ERK1/2, Bcl2 and Sorcin in C. Tubular Adenocarcinoma, 100X (Left), Graph representing the number of patients with Tubular Adenocarcinoma exhibiting ERK1/2, Bcl2 and Sorcin expression (Right) D. Signet Ring Cell Carcinoma (Left), Graph representing the number of patients with Signet Ring Cell Carcinoma exhibiting ERK1/2, Bcl2 and Sorcin expression (Right)

Article Snippet: After antigen retrieval, the sections were blocked by peroxidase solution and immunostained with ERK1/2 (9911; Cell Signalling Technology); Bcl2 (MA5-11757; Invitrogen) and Sorcin (A6751; ABclonal) primary antibodies diluted at 1:500.

Techniques: Staining, Immunostaining, Expressing

Journal: Asian Pacific Journal of Cancer Prevention

Article Title: Comparative Study of ERK1/2, Bcl2, and Sorcin with Clinicopathological Characteristics of Gastric carcinoma: Tubular Adenocarcinoma Vs Signet Ring Cell Carcinoma

doi: 10.31557/apjcp.2025.26.5.1581

Figure Lengend Snippet: Figure 3. Kaplan-Meier and Cox-Proportional Analysis of A. Tubular Adenocarcinoma and Signet Ring Cell Carcinoma B. ERK1/2, Bcl2 and Sorcin in Tubular Adenocarcinoma C. ERK1/2, Bcl2 and Sorcin in Signet Ring Cell Carcinoma

Article Snippet: After antigen retrieval, the sections were blocked by peroxidase solution and immunostained with ERK1/2 (9911; Cell Signalling Technology); Bcl2 (MA5-11757; Invitrogen) and Sorcin (A6751; ABclonal) primary antibodies diluted at 1:500.

Techniques:

Journal: Asian Pacific Journal of Cancer Prevention

Article Title: Comparative Study of ERK1/2, Bcl2, and Sorcin with Clinicopathological Characteristics of Gastric carcinoma: Tubular Adenocarcinoma Vs Signet Ring Cell Carcinoma

doi: 10.31557/apjcp.2025.26.5.1581

Figure Lengend Snippet: Figure 4. The Heatmap Representing the Relationship between ERK1/2, Bcl2 and Sorcin Expression and Clinicopathological Factors in A. Tubular Adenocarcinoma (TA) and B. Signet Ring Cell carcinoma (SRCC)

Article Snippet: After antigen retrieval, the sections were blocked by peroxidase solution and immunostained with ERK1/2 (9911; Cell Signalling Technology); Bcl2 (MA5-11757; Invitrogen) and Sorcin (A6751; ABclonal) primary antibodies diluted at 1:500.

Techniques: Expressing

Journal: Cellular and molecular life sciences : CMLS

Article Title: Sorcin promotes migration in cancer and regulates the EGF-dependent EGFR signaling pathways.

doi: 10.1007/s00018-023-04850-4

Figure Lengend Snippet: Fig. 6 Role of Sorcin in cell migration after EGF and IGF treatment. Wound-healing assay in H1299 cells cultured in serum-free medium (SF) or in the presence of EGF and IGF, in control experiments (siNC) and upon silencing of Sorcin (siSRI). Images were acquired at 0 h and 24 h after each single treatment. Quantification of wound-healing assay calculated as percentage of wound closure: ((At0 – At1)/ At0) × 100), where At0 is the initial wound area and At1 is the wound area n hours after the initial scratch. Error bars indicate means ± SEM. **p < 0.01, ***p < 0.001 and ****p < 0.0001 as determined by Student’s t test (n = 3). Scale bars, 200 µm

Article Snippet: Western blotting was performed loading 30 μg of lysates and using the following primary antibodies: rabbit monoclonal EGFR (1:1000 in 5%BSA-T-TBS solution) (D38B1, #4267, Cell Signaling), rabbit monoclonal Phospho-EGF Receptor (1:1000 in 5%BSA-T-TBS solution) (Tyr1068, #3777 Cell Signaling, Danvers, MA, USA), rabbit monoclonal p44/42 MAPK (Erk1/2) (1:1000 in 5%BSA-T-TBS solution) (137F5, #4695 Cell Signaling, Danvers, MA, USA), rabbit monoclonal Phospho-ERK1/ERK2 (P44/ P42 MAPK) (1:1000 in 5%BSA-T-TBS solution) (T202/ Y204 # MAB-94112 Immunological Science, Italy), rabbit polyclonal CHD2 (1:1000 in 5%BSA-T-TBS solution) (#ab182013, Abcam), mouse monoclonal SLUG (A-7) (1:200 in 5%BSA-T-TBS solution) (#sc-166476 Santa Cruz Biotechnology, Heidelberg, Germany), mouse monoclonal SNAI1 (G-7) (1:200 in 5%BSA-T-TBS solution) (#sc-271977 Santa Cruz Biotechnology, Heidelberg, Germany), mouse monoclonal Sorcin (39-M) (1:200 in 5%BSA-T-TBS solution) (#sc-100859 Santa Cruz Biotechnology, Heidelberg, Germany), mouse monoclonal GAPDH (1:2000 in 5%BSA-T-TBS solution) (#TA802519, OriGene Technologies, Rockville, USA), mouse monoclonal α-Tubulin B-5–1-2 (1:3000 in 5%BSA-T-TBS solution) (#T5168, Sigma-Aldrich, Milan, Italy).

Techniques: Migration, Wound Healing Assay, Cell Culture, Control